Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 3:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–56 of 56 matching trials from the live ClinicalTrials.gov search.
Conditions
Metastatic Melanoma
Interventions
Photoimmunotherapy
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Non-Melanoma Skin Cancers
Interventions
IFx-Hu2.0
Biological
Lead sponsor
TuHURA Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 1 more
Conditions
Glioblastoma, Astrocytoma, Grade IV
Interventions
EGFR(V)-EDV-Dox
Drug
Lead sponsor
Engeneic Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
12
States / cities
Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 8 more
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Nivolumab + ipilimumab, Nivolumab + ipilimumab + platinum-based chemotherapy, Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy, Other dual-immuno-oncology therapy with chemotherapy
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fleming Island, Florida
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
ALLO-605, ALLO-647, Fludarabine, Cyclophosphamide
Genetic · Biological · Drug
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Denver, Colorado • Austin, Texas • Houston, Texas + 1 more
Conditions
Select Advanced Solid Tumors
Interventions
MEDI0562, Tremelimumab, Durvalumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 100 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Santa Monica, California • Chicago, Illinois • St Louis, Missouri + 6 more
Conditions
Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
Interventions
Cemiplimab, RP1
Drug · Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 11 more